Education
About Us
Working with TipRanks
Follow Us
Elicera Therapeutics AB (DE:8E8)
FRANKFURT:8E8
Total Valuation
Elicera Therapeutics AB has a market cap or net worth of €24.37M. The enterprise value is €237.25M.
Market Cap€24.37M
Enterprise Value€237.25M
Share Statistics
Elicera Therapeutics AB has 48,535,545 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48,535,545
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Elicera Therapeutics AB’s return on equity (ROE) is -0.75 and return on invested capital (ROIC) is -76.81%.
Return on Equity (ROE)-0.75
Return on Assets (ROA)-0.63
Return on Invested Capital (ROIC)-76.81%
Return on Capital Employed (ROCE)-0.77
Revenue Per Employee0.00
Profits Per Employee-8.97M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Elicera Therapeutics AB is ―. Elicera Therapeutics AB’s PEG ratio is 0.54.
PE Ratio―
PS Ratio0.00
PB Ratio10.19
Price to Fair Value10.19
Price to FCF-11.04
Price to Operating Cash Flow-12.16
PEG Ratio0.54
Income Statement
In the last 12 months, Elicera Therapeutics AB had revenue of 0.00 and earned -17.41M in profits. Earnings per share was -0.38.
Revenue0.00
Gross Profit0.00
Operating Income-17.94M
Pretax Income-17.41M
Net Income-17.41M
EBITDA-17.40M
Earnings Per Share (EPS)-0.38
Cash Flow
In the last 12 months, operating cash flow was -21.55M and capital expenditures 0.00, giving a free cash flow of -21.55M billion.
Operating Cash Flow-21.55M
Free Cash Flow-21.55M
Free Cash Flow per Share-0.44
Dividends & Yields
Elicera Therapeutics AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.06
52-Week Price Change147.72%
50-Day Moving Average0.49
200-Day Moving Average0.51
Relative Strength Index (RSI)45.91
Average Volume (3m)0.00
Important Dates
Elicera Therapeutics AB upcoming earnings date is Apr 28, 2026, Before Open (Confirmed).
Last Earnings DateFeb 13, 2026
Next Earnings DateApr 28, 2026
Ex-Dividend Date―
Financial Position
Elicera Therapeutics AB as a current ratio of 6.75, with Debt / Equity ratio of 0.00%
Current Ratio6.75
Quick Ratio6.75
Debt to Market Cap0.00
Net Debt to EBITDA1.43
Interest Coverage Ratio-2.28K
Taxes
In the past 12 months, Elicera Therapeutics AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Elicera Therapeutics AB EV to EBITDA ratio is -12.25, with an EV/FCF ratio of -9.89.
EV to Sales0.00
EV to EBITDA-12.25
EV to Free Cash Flow-9.89
EV to Operating Cash Flow-9.89
Balance Sheet
Elicera Therapeutics AB has €24.85M in cash and marketable securities with €0.00 in debt, giving a net cash position of €24.85M billion.
Cash & Marketable Securities€24.85M
Total Debt€0.00
Net Cash€24.85M
Net Cash Per Share€0.51
Tangible Book Value Per Share€0.51
Margins
Gross margin is 100.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin100.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Elicera Therapeutics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―